News
InvestorsHub on MSN4d
Nyxoah Shares Climb Following FDA Clearance of Genio Device for Sleep Apnea Treatment
Nyxoah SA (NASDAQ:NYXH) saw its stock rise 9.4% after the FDA granted approval for its Genio system designed to treat ...
Zacks.com on MSN15h
Nyxoah Secures FDA Clearance for Genio System to Treat Sleep Apnea
NYXH wins FDA approval for its leadless, battery-free Genio sleep apnea therapy, backed by strong trial results.
After years of being cleared on the European market, Nyxoah’s neuromodulation therapy for obstructive sleep apnea has now ...
“AI can be used as a gym – a place for training, challenge, and growth – or as a diet pill, a way to bypass effort in the ...
The FDA has approved the Genio system for the treatment of patients with moderate to severe obstructive sleep apnea.
The FDA has approved the Genio® system for treating patients with moderate to severe obstructive sleep apnea (OSA) with an ...
Nyxoah is in the midst of a lawsuit brought on by Inspire Medical Systems alleging infringement of several patents related to its recently-cleared offering, Genio.
GlobalData on MSN4d
FDA approves Nyxoah’s Genio system for obstructive sleep apnoea
The system is compatible with 1.5T and 3T magnetic resonance imaging scans and eliminates the need for an implanted battery.
Nyxoah announced today that it received FDA approval for its Genio neuromodulation device for treating sleep apnea.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback